Evogene

Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. It operates through the following segments: Agriculture, Industrial Applications, and Human Health. The Agriculture segment develops seed traits, agrochemical products, and agro biological products to improve plant performance. The Industrial Applications focuses on the development and commercialization of improved castor bean seeds for industrial uses. The Human Health segment involves discovery and development of human microbiome-based therapeutics. The company was founded by Amir Barzilay and Hagai Karchi on October 10, 1999 and is headquartered in Rehovot, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Evogene reports revenue growth and strategic collaborations driving future prospects

Evogene's Q1 2024 performance showed revenue growth, decreased losses, and strategic milestones achieved by key subsidiaries.
The company's strengths lie in innovative collaborations, a unique CPB platform, and successful revenue-driving partnerships.
Challenges include financial management, operational execution, and logistical considerations for seed supply.
Opportunities for growth stem from promising future achievements, strategic partnerships, and market differentiation through innovation.

Evogene reports revenue surge and promising developments in key segments

Evogene demonstrated strong revenue growth in the first half of 2024 and made progress in reducing losses, reflecting improving financial performance.
Casterra's expanding market reach and revenue growth opportunities, coupled with Biomica's promising trial results, position Evogene well for future growth.
While facing challenges in achieving profitability and managing cash flow, Evogene's focus on operational efficiency and market expansion presents avenues for sustainable growth.

Evogene reports Q3 revenue decline but anticipates growth opportunities

Evogene's Q3 2024 performance reflected a decline in revenues but improved cost management, with a focus on enhancing cash reserves.
The company's strengths lie in upcoming revenue growth, strategic collaborations, and plans to fortify its financial position.
Challenges include market uncertainties, operational losses, and addressing investor concerns for sustained growth and profitability.
Opportunities exist for Evogene to capitalize on its achievements, explore new avenues, and drive value creation for stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Eastside Distilling

Intec Parent

OrganiGram Holdings Inc.

Marijuana legalization is a hot topic & some penny stocks are benefiting in 2021. The post Best Penny Stocks To Buy Before Marijuana Legalization?

Best Penny Stocks To Buy Before Marijuana Legalization? 4 To Watch Now

REHOVOT, Israel, July 6, 2021 /PRNewswire/ -- AgPlenus Ltd., a company designing effective, sustainable crop protection products by leveraging computational biology and chemistry, and a subsidiary of Evogene Ltd.

AgPlenus Announces Positive Results for a Herbicide Resistance Trait to its Leading Herbicide Product Candidate

AFC Gamma

Arena Pharmaceuticals

Canopy Growth

Corbus Pharmaceuticals Holdings

India Globalization Capital

SNDL Inc.

Tilray Brands

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues to take shape in 2021.

Pot Stocks in Focus: Cannabis-Based Pharmaceutical Trials

REHOVOT, Israel, June 23, 2021 /PRNewswire/ --Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announced today that its Board of Directors has resolved to appoint Ms.

Evogene Announces Ms. Sarit Firon to become Evogene's Chairperson of the Board

Canonic, a subsidiary of Evogene, will bring its unique cannabis products to the Israeli cannabis market in 2022. The company has been hard at work deciphering the cannabis genome and breeding special strains to treat specific conditions, like chronic pain and inflammation.

Evogene: Bullish With Canonic's Entry Into Israeli Medical Cannabis Markets

Aurora Cannabis

Cara Therapeutics

Greenlane Holdings

GrowGeneration Corp

HEXO Corp

Innovative Industrial Properties

Coffee Holding

Akerna Corp

Neptune Wellness Solutions Inc.

Power REIT

Village Farms International

12 Cannabis Stocks That Lit Up Wall Street This Week

Evogene Ltd. (EVGN) CEO Ofer Haviv on Q1 2021 Results - Earnings Call Transcript

Computational biology company Evogene Ltd. (NASDAQ:EVGN) reported Wednesday its first-quarter financial results with revenue of $333,000, compared to $75,000 in the same period of 2020.

Shares of Medical Cannabis-Related Evogene Slightly Up On First Quarter Earnings

REHOVOT, Israel, May 26, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across several market segments, announces today its financial results for the first quarter of 2021.

Evogene Reports First Quarter 2021 Financial Results

REHOVOT, Israel, May 25, 2021 /PRNewswire/ -- Lavie Bio Ltd., a leading ag-biologicals company focusing on improving food quality, sustainability, and agriculture productivity through the introduction of microbiome-based products, and a subsidiary of Evogene Ltd.

Lavie Bio Announces the Appointment of Russ Putland as Vice President Commercial

REHOVOT, Israel, May 12, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announces today that it will release its financial results for the first quarter of 2021 on Wednesday, May 26 th, 2021.

Evogene Financial Results and Earnings Announcement Schedule for the First Quarter of 2021

REHOVOT, Israel, April 19, 2021 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd.

Biomica to Present at Jefferies Microbiome-Based Therapeutics Summit, on April 22nd, 2021

PAVmed

Savara

Synlogic

Analysts say these penny stocks are a buy right now & have bullish price targets to boot. The post Penny Stocks To Buy According To Analysts With Price Targets Up to 341% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy According To Analysts With Price Targets Up to 341%

The stock price of Evogene Ltd. (Nasdaq: EVGN) increased by over 9% pre-market.

EVGN Stock: Over 9% Increase Pre-Market Explanation

REHOVOT, Israel, April 13, 2021 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd.

Biomica Announces Positive Pre-Clinical Results, Demonstrating Efficacy of BMC128 in Melanoma

Canonic, a subsidiary of Evogene, has a strategy to enter the Israeli medical cannabis market. Canonic, using Evogene's CPB platform, is developing innovative cannabis strains to meet industry needs.

Evogene's Canonic Positioned To Enter Israeli Medical Cannabis Market

REHOVOT, Israel, April 7, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), a leading computational biology company today announced that it will hold virtual investor and analyst days, in both Hebrew and English, via Zoom webinars.

Evogene to Hold Virtual Investor & Analyst Days

REHOVOT, Israel , April 2, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2020 with the U.S. Securities and Exchange Commission (the "SEC").

Evogene Files Annual Report for the Year Ended December 31, 2020

REHOVOT, Israel and TEL-AVIV, Israel, March 25, 2021 /PRNewswire/ -- Canonic Ltd., a subsidiary of Evogene Ltd.

Canonic of Evogene Group and Tikun Olam (Israel)-Cannbit, sign production and distribution agreements for Canonic products in Israel

Biomica released impressive pre-clinical data for its rationally designed 4 strand microbiome therapeutic candidate BMC128 in immuno-oncology presented at the 5th Annual European Microbiome Drug Development conference on January 28. BMC128 is expected to be tested in human clinical trials in Israel during the second half of this year.

Evogene's Subsidiary Biomica: Impressive Pre-Clinical Data For Its Microbiome Therapeutic BMC128

ST. LOUIS, Mo. and REHOVOT, Israel, March 17, 2021 /PRNewswire/ -- Plastomics, Inc., an agricultural biotech company, developing a step change in trait delivery technology, and Evogene Ltd.

Plastomics and Evogene's Ag-Seed division enter a collaborative agreement targeting novel insect control traits for soybean

Evogene Ltd. (EVGN) CEO Ofer Haviv on Q4 2020 Results - Earnings Call Transcript

REHOVOT, Israel, March 3, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading computational biology company targeting to revolutionize life-science product discovery and development across several market segments, announces today its financial results for the...

Evogene Reports Fourth Quarter and Full Year 2020 Financial Results

Evogene Ltd. is a leading computational biology company aiming to "revolutionize" the discovery and development of life sciences products covering human health, agriculture, and industrial purposes.

Evogene: Ambitious Computational Biology Company Aims To Reward Patient Investors

TEL AVIV and REHOVOT, Israel, Feb. 24, 2021 /PRNewswire/ -- Cannbit Ltd., a subsidiary of Tikun Olam-Cannbit Ltd. (TASE: TKUN), a leading medical cannabis company, and Canonic Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), focused on the development of medical cannabis...

Cannbit, subsidiary of Tikun Olam-Cannbit, and Canonic of Evogene group announce collaboration for the development of novel medical cannabis products

News for Evogene Stock (EVGN)